Scholarlink

<p>Relapsed/refractory lymphoid malignancies lack effective treatment selection strategies. We evaluated high-throughput ex vivo drug profiling in 26 patients, achieving successful profiling in 22 cases. We found broad ex vivo resistance to conventional chemotherapy but sensitivity to BH3 mimetics. Notably, p53-aberrant samples showed increased sensitivity to dasatinib and PI3K inhibitors across subtypes. These findings demonstrate feasibility of functional precision medicine pipelines in lymphoid malignancies and identify actionable vulnerabilities warranting further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Arvid Cederlund,
  • Nona Struyf,
  • Lucia Rico Pizarro,
  • Päivi Östling,
  • Kristina Sonnevi,
  • Björn Engelbrekt Wahlin,
  • Tom Erkers

摘要

Relapsed/refractory lymphoid malignancies lack effective treatment selection strategies. We evaluated high-throughput ex vivo drug profiling in 26 patients, achieving successful profiling in 22 cases. We found broad ex vivo resistance to conventional chemotherapy but sensitivity to BH3 mimetics. Notably, p53-aberrant samples showed increased sensitivity to dasatinib and PI3K inhibitors across subtypes. These findings demonstrate feasibility of functional precision medicine pipelines in lymphoid malignancies and identify actionable vulnerabilities warranting further investigation.